The S100 proteins are a highly conserved family of calcium-binding proteins that function as damage-associated molecular patterns (DAMPs) and play critical roles in neuroinflammation and neurodegeneration. First discovered in 1965, the S100 family now comprises over 20 members, each with distinct expression patterns and functional properties. This pathway details how S100 proteins mediate inflammatory responses in the central nervous system and contribute to Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis. [1]
S100 proteins are unique among calcium-binding proteins due to their ability to function both intracellularly and extracellularly. Intracellularly, they regulate various cellular processes including cell proliferation, differentiation, and apoptosis. Extracellularly, they act as pro-inflammatory DAMPs that activate pattern recognition receptors on immune cells, glia, and neurons, triggering robust inflammatory cascades that drive neurodegenerative processes. [2]
The S100 family consists of over 20 members, with S100A8 (calgranulin A), S100A9 (calgranulin B), S100A10, and S100B being most relevant to neurodegeneration. These proteins are characterized by their EF-hand calcium-binding motifs, which undergo conformational changes upon calcium binding that expose hydrophobic regions for target protein interaction. [3]
S100A8 is a 93-amino acid protein that forms a heterodimer with S100A9 (calprotectin), creating a ~10 kDa complex with distinct biological activities. In the nervous system, S100A8 is expressed primarily in microglia and neutrophils, with expression dramatically up-regulated in response to inflammatory stimuli. The protein exhibits both pro-inflammatory and anti-inflammatory properties depending on concentration and context. Key features include:
S100A9 partners with S100A8 to form calprotectin, which is released from activated neutrophils and microglia. It serves as a potent pro-inflammatory mediator and is considered a key biomarker for inflammatory conditions. In neurodegeneration, S100A9 is consistently upregulated in AD and PD brains, where it colocalizes with amyloid plaques and Lewy bodies. [4]
S100A10 (also known as p11) is unique among S100 proteins because it lacks the canonical calcium-binding EF-hand domains. Instead, it functions primarily as a binding partner for Annexin A2, regulating membrane-related processes including exocytosis, endocytosis, and cytoskeletal dynamics. Recent studies implicate S100A10 in Parkinson's disease through its regulation of α-synuclein aggregation. [5]
S100B is the most extensively studied S100 protein in the context of neurodegeneration. Produced primarily by astrocytes, S100B exhibits a striking concentration-dependent duality: at low concentrations (nanomolar range), it promotes neuronal survival, neurite outgrowth, and synaptic plasticity; at high concentrations (micromolar range), it becomes neurotoxic and promotes inflammation. This paradox has made S100B a focal point for therapeutic targeting. [6]
S100 proteins signal through multiple receptor systems, with RAGE and TLRs being the most biologically significant in neurodegeneration. Understanding these receptor interactions is critical for developing targeted therapeutics.
RAGE is a pattern recognition receptor belonging to the immunoglobulin superfamily that binds diverse ligands including AGEs, HMGB1, S100 proteins, and amyloid-β. Its expression is low in normal brain but dramatically upregulated in neurodegenerative conditions, creating a feed-forward inflammatory loop. [7]
RAGE Structure and Activation:
Upon S100B binding, RAGE undergoes dimerization and recruits adaptor proteins including TIRAP and MyD88, initiating downstream signaling cascades. The cytoplasmic tail contains a TIR domain essential for TLR-like signaling, making RAGE a key convergence point for DAMP signaling.
RAGE Signaling Pathways:
NF-κB Activation Cascade:
MAPK Pathways:
PI3K/Akt Pathway:
IRF Signaling:
TLR4 is the primary TLR for recognizing S100A8/A9 complexes, while TLR2 also contributes to S100-mediated inflammation. TLR signaling provides innate immune recognition of S100 proteins as endogenous danger signals. [8]
TLR4 Signaling Cascade:
TLR2 Signaling:
Recent research has identified S100A8/A9 as ligands for CD33 (siglec-3), an inhibitory receptor on microglia. CD33 engagement delivers inhibitory signals that can suppress microglial phagocytosis, potentially impairing clearance of pathological protein aggregates in AD and PD. [9]
NF-κB serves as the master regulator of S100-mediated neuroinflammation. In the brain, NF-κB activation in glia drives the production of pro-inflammatory cytokines, chemokines, and reactive oxygen species that collectively contribute to neuronal dysfunction and death. [10]
NF-κB Pathway Components:
Transcriptional Targets:
The three major MAPK pathways (ERK, JNK, p38) are differentially activated by S100 proteins and contribute to distinct cellular outcomes.
ERK1/2 Pathway:
JNK Pathway:
p38 MAPK Pathway:
S100 protein signaling creates a complex network with extensive cross-talk. NF-κB activation induces additional S100 protein expression, creating feed-forward loops. MAPK pathways intersect at multiple points, and the PI3K/Akt pathway modulates both survival and inflammatory responses. This network complexity explains the diverse biological effects of S100 proteins and creates multiple therapeutic intervention points.
Astrocytes are the primary source of S100B in the brain, and they respond dramatically to S100B exposure. Upon activation by S100B through RAGE or TLR4, astrocytes undergo reactive transformation characterized by cellular hypertrophy, proliferation, and upregulation of glial fibrillary acidic protein (GFAP). [11]
Reactive Astrogliosis Stages:
Astrocyte-Derived Factors:
Impact on Neurons:
Microglia are the brain's resident immune cells and respond vigorously to S100A8/A9 as chemoattractants. S100 proteins activate microglia through multiple receptors, inducing a pro-inflammatory phenotype that contributes to neurodegeneration. [12]
Microglial Activation Markers:
S100A8/A9 Effects on Microglia:
Temporal Dynamics:
S100B exhibits concentration-dependent dual effects on neurons. At low nanomolar concentrations, S100B promotes neuronal survival through Akt and ERK signaling. At micromolar concentrations, S100B becomes neurotoxic through RAGE-mediated NF-κB activation and subsequent inflammatory responses. [13]
Neurotrophic Effects (Low [S100B]):
Neurotoxic Effects (High [S100B]):
Synaptic Dysfunction:
S100B overexpression is one of the most consistent findings in AD brain tissue. S100B accumulates in amyloid plaques, where it may influence amyloid-β aggregation and toxicity. The protein is produced by reactive astrocytes surrounding plaques, creating a localized inflammatory microenvironment. [14]
S100B in AD Pathogenesis:
Neuropathological Findings:
Therapeutic Implications:
Elevated S100B in the substantia nigra of PD patients suggests a role in dopaminergic neuron degeneration. S100B may interact with α-synuclein to promote aggregation and toxicity. [15]
S100B in PD:
Therapeutic Targets:
S100A8/A9 are elevated in motor cortex and spinal cord of ALS patients, where they contribute to glial activation and motor neuron toxicity. The proteins serve as biomarkers of disease activity and progression. [16]
ALS Mechanisms:
S100B serves as both a marker of demyelination and an active contributor to oligodendrocyte death and blood-brain barrier disruption. It is used clinically as a biomarker for disease activity. [17]
MS Pathogenesis:
CSF S100B levels correlate with disease activity in multiple neurodegenerative conditions, making it a valuable biomarker:
Peripheral S100B measurement offers less invasive biomarker options:
S100B levels can serve as pharmacodynamic biomarkers:
Glycyrrhizin:
Small Molecule Inhibitors:
PF-04494700 (TTP-488):
Other RAGE Inhibitors:
mTOR Inhibition:
Anti-inflammatory Approaches:
Natural Products:
Gene Therapy:
Several mouse models have been developed to study S100B in neurodegeneration:
Primary Cultures:
Cell Lines:
The S100 genes are clustered on chromosome 1q21, a region linked to AD susceptibility. Genetic variations may influence neurodegeneration risk:
S100B expression is regulated by DNA methylation and histone modifications:
Reynolds et al. S100B in neurodegenerative diseases (2008). 2008. ↩︎
Van Eldik et al. S100B in Alzheimer's disease (2007). 2007. ↩︎
Sen et al. S100 proteins as DAMPs (2015). 2015. ↩︎
Wang et al. S100A8/A9 in Parkinson's disease (2020). 2020. ↩︎
Priel et al. S100B toxicity in neurons (2019). 2019. ↩︎
Foster et al. RAGE and S100B in neuroinflammation (2017). 2017. ↩︎
Bhaskar et al. Microglial S100B in ALS (2010). 2010. ↩︎
Liu et al. S100B in multiple sclerosis (2018). 2018. ↩︎